EMEA-001864-PIP02-19
Key facts
Invented name |
Takhzyro
|
Active substance |
lanadelumab
|
Therapeutic area |
Other
|
Decision number |
P/0140/2020
|
PIP number |
EMEA-001864-PIP02-19
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Prevention of acquired angioedema attacks
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Takeda Pharmaceuticals International AG Ireland Branch
E-mail: medinfoemea@takeda.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|